Open AccessElabela as a Novel Marker; Well-Correlated with WIfI Amputation Risk Score in Patients with Lower Extremity Arterial Disease
Author(s) -
Mehmet Kaplan,
Fethi Yavuz,
Gizem Kaplan,
Nurbanu Bursa,
Ertan Vuruşkan,
Murat Sucu
Publication year - 2020
Publication title -
the anatolian journal of cardiology
Language(s) - English
Resource type - Journals
eISSN - 2149-2271
pISSN - 2149-2263
DOI - 10.14744/anatoljcardiol.2020.17329
Subject(s) - medicine , amputation , cardiology , disease , arterial disease , ankle , surgery , vascular disease
Worldwide, over 200 million people are diagnosed with lower extremity arterial disease (LEAD). LEAD significantly increases the risk of death and amputation of the lower limb. A new classification system (WIfI) has been proposed to initially assess all patients with ischemic rest pain or wounds and also predicts 1-year amputation risk. Elabela is a bioactive peptide and a part of the apelinergic system, which has beneficial effects on body fluid homeostasis and cardiovascular health. We aimed to investigate serum Elabela levels in LEAD.